Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients
The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.
29 Aug 17:15 · News-Medical